Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology, Inc. reported under an 8-K that it issued a press release titled “MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025.” The company uses this filing to formally share that update with the market and attaches the full press release as an exhibit, incorporating it by reference.
The disclosure is presented as an “Other Events” item, meaning it is an informational update rather than a financial report or major transaction. The company also includes standard cautionary language that statements about its development programs, including the Ateganosine clinical program, are forward-looking and subject to significant risks and uncertainties.
MAIA Biotechnology, Inc. reported that its Chief Executive Officer, Vlad Vitoc, presented on telomere-targeting efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation. The company issued a press release titled “MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation,” which is attached as an exhibit and incorporated by reference.
The report also reiterates that any statements about future plans, development timelines, regulatory approvals, market potential, or other non-historical matters are forward-looking statements and subject to significant risks and uncertainties. MAIA highlights factors such as the progress and results of its preclinical and clinical studies, regulatory timing, manufacturing capabilities, market acceptance, market size and growth, and intellectual property protection as key areas that could cause actual outcomes to differ materially from these forward-looking comments.
MAIA Biotechnology reported a wider quarterly loss and flagged liquidity risk in its Q3 results. For the quarter ended September 30, 2025, the company posted a net loss of $8.9 million as operating expenses rose, driven by research and development.
Cash was $10.9 million with working capital of approximately $1.76 million. Management stated there is substantial doubt about the company’s ability to continue as a going concern within one year without additional financing. Operating cash outflow was $11.8 million for the nine months, partially offset by financing inflows of $13.1 million, including at-the-market share sales and multiple private placements.
Quarterly operating expenses were $9.36 million (R&D $6.36 million; G&A $3.00 million). The warrant liability decreased to $1.75 million, contributing to other income. Shares outstanding were 34.45 million at quarter-end; authorized common shares were increased to 150 million earlier in the year. As of November 7, 2025, common shares outstanding were 37,032,307.
MAIA Biotechnology reported two upcoming scientific presentations and made the materials available as exhibits. The company prepared a THIO-104 Phase 3 trial-in-progress poster for immune checkpoint inhibitor–resistant advanced NSCLC, presented at SITC 2025 on November 7, 2025, and a THIO-101 Phase 2 trial-in-progress poster for the same setting, presented on November 10, 2025.
The THIO-104 poster is filed as Exhibit 99.1 and the THIO-101 poster as Exhibit 99.2, with both to be posted on the company’s website on their respective presentation dates. The company notes these materials contain forward-looking statements.
MAIA Biotechnology filed an 8-K noting two updates. The company announced a trial-in-progress poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting its pipeline activities. MAIA also reported enrolling five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial.
MAIA Biotechnology reported under Regulation FD that it presented a scientific poster titled “Presentation 1: A Phase 2 Study of Ateganosine (THIO; 6‑thio‑2’-deoxyguanosine) in combination with immune checkpoint inhibitor in patients with advanced NSCLC: THIO‑101 Trial.”
The poster was presented at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 24, 2025 and was posted to the company’s website the same day. The poster is furnished as Exhibit 99.1. The company notes the poster contains forward‑looking statements.
MAIA Biotechnology furnished a Regulation FD Form 8-K to share a press release titled “MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer.” The company states this information is being provided for disclosure purposes.
The Item 7.01 materials are deemed “furnished” rather than “filed,” so they are not subject to Section 18 of the Exchange Act and are not incorporated by reference into other filings. Exhibits include the press release and scientific posters for the THIO-101 and THIO-104 trials, along with the cover page interactive data file.
MAIA Biotechnology entered a Securities Purchase Agreement for a private placement of 603,769 shares of common stock at $1.22 per share, together with warrants to purchase up to 603,769 shares, for expected gross proceeds of approximately $736,600. The warrants are exercisable at $1.52, begin six months after issuance, and expire three years from the issuance date.
The securities are being issued as restricted under Rule 144 with no registration rights and are offered in reliance on Section 4(a)(2) and/or Rule 506. Closing is expected on October 15, 2025, subject to customary closing conditions. The company plans to use net proceeds to fund the starting cost for Step 1 of Part C of its Phase II THIO‑101 trial and for working capital.
MAIA Biotechnology filed a current report describing a new treasury strategy that adds digital assets to how it manages its corporate funds. The company announced a plan to hold a portion of its treasury in a diversified portfolio focused on top-tier cryptocurrency assets, as detailed in an accompanying press release.
This move formally introduces exposure to cryptocurrencies at the corporate level, in addition to traditional cash and financial assets. The filing emphasizes that statements about this strategy and its future impact are forward-looking and subject to risks and uncertainties, including broader business, regulatory, and market factors affecting the company’s operations and product development.
MAIA Biotechnology reported a director stock-option grant disclosed on a Form 4. Stan V. Smith, a company director, received an award of